Nasser Hanna, MD
ASCO has updated its guidelines for first- and second-line treatment of patients with stage IV non–small cell lung cancer (NSCLC). The organization has created new recommendations regarding the use of immunotherapy, and updated advice on targeted therapies for patients with mutations in the EGFR, ALK,
The organization also noted that while immunotherapy can provide a survival benefit in some cases, not every patient will respond to treatment, and physicians still do not fully understand optimal sequencing of immune checkpoint therapy and other recommended agents.
Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update [published online August 14, 2017]. J Clin Oncol. doi: 10.1200/JCO.2017.74.6065.
... to read the full story